Intas Pharmaceuticals Limited is an Indian pharmaceutical company headquartered in

Ahmedabad Ahmedabad ( ; Gujarati: Amdavad ) is the most populous city in the Indian state of Gujarat. It is the administrative headquarters of the Ahmedabad district and the seat of the Gujarat High Court. Ahmedabad's population of 5,570,585 (per t ...

, Gujarat.

History

The company was founded by a Jain pharmacist Hasmukh Chudgar in 1977 and was incorporated in 1985. In 2013, ChrysCapital acquired 16.14% stake in the company, and in 2015, ChrysCapital subsequently sold 10.13% to Singapore-based Temasek Holdings and in 2017, it further diluted 3.01% stake to Capital International. Though, by May 2020, ChrysCapital bought back Capital International's stake. Currently, the Chudgar family, owns 83.85% stake in the company, with 10.13% being held by Temasek Holdings, and 6.02% by ChrysCapital. As of March 2021, the company is operating 19 manufacturing facilities globally - 13 in India, 5 in the UK, and 1 in Mexico. The company has set up a new manufacturing facility in PHARMEZ ( Bavla, near

) with capacity to manufacture and export more than 1 billion solid dosages and 5 million

injectables An injection (often and usually referred to as a "shot" in US English, a "jab" in UK English, or a "jag" in Scottish English and Scots) is the act of administering a liquid, especially a drug, into a person's body using a needle (usually a hypo ...

Divisions

Biologics Unit (formerly, Intas Biopharmaceuticals)

In 2006, an independent biotechnology division of Intas Pharmaceuticals was incorporated as Intas Biopharmaceuticals by Urmish Chudgar, a

hematologist Hematology (American and British English spelling differences#ae and oe, always spelled haematology in British English) is the branch of medicine concerned with the study of the cause, prognosis, treatment, and prevention of diseases related to ...

. Later in 2012-13, the subsidiary was merged with the parent company Intas Pharmaceuticals Limited. This division is involved in development and manufacturing of biosimilar products based on recombinant DNA and

monoclonal antibodies A monoclonal antibody (mAb, more rarely called moAb) is an antibody produced from a cell Lineage made by cloning a unique white blood cell. All subsequent antibodies derived this way trace back to a unique parent cell. Monoclonal antibodies ca ...

. The company faced an EU-GMP ( Good Manufacturing Practice) audit in December 2006, to seek approval for a clinical trial of its biosimilar Filgrastim in Europe and was certified as EU-GMP compliant in April 2007, becoming the first company in India to receive such certification. In 2015, the company launched its first biosimilar product, Filgrastim in Europe, to treat patients with advanced HIV infection and immune system disorders such as

neutropenia Neutropenia is an abnormally low concentration of neutrophils (a type of white blood cell) in the blood. Neutrophils make up the majority of circulating white blood cells and serve as the primary defense against infections by destroying bacteria ...

. Apart from EU-GMP certification, the company has approvals from MCC South Africa, Gulf Cooperation Council (GCC),

Syria Syria ( ar, سُورِيَا or سُورِيَة, translit=Sūriyā), officially the Syrian Arab Republic ( ar, الجمهورية العربية السورية, al-Jumhūrīyah al-ʻArabīyah as-Sūrīyah), is a Western Asian country loc ...

, Yemen, Belarus and several other national health authorities for its manufacturing facility and products.

Subsidiaries

Accord Healthcare

London-headquartered Accord Healthcare is a fully-owned subsidiary of Intas Pharmaceuticals, which deals with large-scale generic pharmaceuticals in Europe and North America markets. It also manages an American R&D unit which is located at

Research Triangle Park Research Triangle Park (RTP) is the largest research park in the United States, occupying in North Carolina and hosting more than 300 companies and 65,000 workers. The facility is named for its location relative to the three surrounding cities ...

, Durham. As of 2018, the company has approval for 89 Abbreviated New Drug Applications and is selling 255 dosing presentations.

Acquisitions

Teva Pharmaceuticals (UK & Ireland)

In 2016, Intas acquired the assets of Teva Pharmaceuticals in the UK and Ireland for US$764 million.

Actavis (UK & Ireland)

In 2017, the company's Accord Healthcare announced acquisition of Actavis UK Ltd. and Actavis Ireland Ltd from Teva Pharmaceutical Industries, for an enterprise value of £603 million. The deal included a portfolio of generic medicines and a manufacturing plant in

Barnstaple Barnstaple ( or ) is a river-port town in North Devon, England, at the River Taw's lowest crossing point before the Bristol Channel. From the 14th century, it was licensed to export wool and won great wealth. Later it imported Irish wool, bu ...

Sanofi's Fawdon Plant

In 2018, Intas' subsidiary Accord Healthcare reopened Sanofi 's Fawdon plant in the UK for manufacturing generic effervescent medicines. The plant was acquired in 2015 after Sanofi closed the facility. This is the fifth manufacturing location for Accord in the country after Harrow, Barnstaple, Haverhill, and Didcot.

Financials

The company had an annual revenue of US$1.8 Billion (₹12,600

crore A crore (; abbreviated cr) denotes ten million (10,000,000 or 107 in scientific notation) and is equal to 100 lakh in the Indian numbering system. It is written as 1,00,00,000 with the local 2,2,3 style of digit group separators (one lakh is e ...

) in 2019 and a profit of $204

Million One million (1,000,000), or one thousand thousand, is the natural number following 999,999 and preceding 1,000,001. The word is derived from the early Italian ''millione'' (''milione'' in modern Italian), from ''mille'', "thousand", plus the au ...

(₹1,248 crore) after taxes in the financial year 2019. The company's 69% of revenue came from international operations in the FY2019 while 31% came from India.

Controversies

In December 2020, the company along with

Mankind Pharma Mankind Pharma is an Indian pharmaceutical and healthcare products company, headquartered in Delhi. The company has products in therapeutic areas ranging from antibiotics, to gastrointestinal, cardiovascular, dermal, and erectile dysfunction m ...

received show-cause notices for selling anti-diabetic medicine without seeking price approval from National Pharmaceutical Pricing Authority.

References

External links

Official site
{{Authority control Indian brands Pharmaceutical companies of India Biotechnology companies of India Pharmaceutical companies established in 1977 Manufacturing companies based in Ahmedabad 1977 establishments in Gujarat